Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most ...

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $40.67, a high estimate of $45.00, and a low estimate of $33.00. This upward trend is evident, with the ...

Alkermes expects that revenue for full-year 2021 will be between $1.1 billion and $1.17 billion. It anticipates GAAP loss per share of $0.53 to $0.78, with adjusted non-GAAP EPS between $0.37 and ...

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model. Find out why ALKS stock is a Buy.

The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one trading days, and it is up a solid 91% over ...